Re-grown mammary tumors that were exposed to (ruxolitinib + afatinib) also exhibited significantly higher levels of phosphorylated p65 NFκB S536, IκB S32 S36, c-Jun S63, AKT T308, ERBB1 Y1173/Y1068, VEGFR2 Y1175, BAD S112, and ERK1/2, and significantly lower levels of ERBB2 Y1289, p70 S6K T389 and mTOR S2448 and P-S6 phosphorylation. The gene discussed is RPS6KB1; the disease is breast cancer.